Osteoid Osteoma

Osteoid osteoma is a benign osteoblastic bone tumour: a small nidus of osteoid tissue, under 2cm, surrounded by reactive bone sclerosis. It is histologically identical to osteoblastoma and is distinguished from it by size and clinical behaviour.

Who. It accounts for 10-12% of benign bone tumours, with an annual incidence of approximately 3 per million, and it outnumbers osteoblastoma 3:1. The peak age is 10-25 years, with 80% of patients under 30; males outnumber females 2:1 to 3:1, and all ethnic groups are equally affected.

Where. The lower extremity carries 50-60% of lesions, the femur and tibia most commonly, and the upper extremity 20%.

Natural history. Untreated, an osteoid osteoma typically causes persistent symptoms for 3-5 years before it resolves spontaneously, which it does in most cases. Approximately 5-10% resolve within 2 years and most take 3-6 years, while some persist beyond 6 years without resolution. Regression occurs as the nidus matures into inactive sclerotic bone and its prostaglandin production gradually ceases.

Risk factors. No clear risk factor has been identified. The tumour is not associated with trauma, infection or inherited conditions, and it is a true neoplasm rather than a reactive process.

The nidus. A central zone of osteoid and woven bone in various stages of maturation, laid down as haphazardly interconnecting trabeculae. The trabeculae are rimmed by a single layer of plump but cytologically bland osteoblasts and sit in a loose, richly vascular fibrous stroma, which carries the unmyelinated nerve fibres that mediate the pain. Mineralisation is variable, and central calcification is common.

The host bone. The nidus is sharply demarcated from the dense reactive (sclerotic) bone around it, and there is no permeation or entrapment of the pre-existing lamellar bone; that circumscription is a key feature. In the cortical type the reactive sclerosis is extensive and disproportionate to the small nidus, which gives the classic radiographic appearance.

View larger

Biopsy. Tissue is not routinely needed when the clinical and CT findings are classic, but it is valuable when the diagnosis is uncertain.

Why it hurts. The nidus produces high levels of prostaglandin E2 (PGE2) through the COX pathway. PGE2 causes local vasodilation and oedema and sensitises nerve fibres, and it produces the characteristic nocturnal pain.

Why at night, and why aspirin works. The night pattern is attributed to the circadian rhythm of prostaglandin production, the fall at night in cortisol, which is anti-inflammatory, and venous stasis during recumbency increasing pressure. COX inhibitors block prostaglandin synthesis, which is why NSAIDs relieve the pain, and aspirin is particularly effective because its COX inhibition is irreversible.

Osteoid osteoma is classified by where the nidus sits in the bone, and the site has important treatment implications. Cortical lesions are ideal for RFA, while intra-articular and subperiosteal lesions may require arthroscopic or open excision to protect the articular cartilage.

Intra-articular and subperiosteal lesions. These sites have less sclerosis and more synovitis, and they often present as synovitis and stiffness rather than classic night pain, so delayed diagnosis is common. CT must interrogate the articular surface carefully.

View larger

Osteoid osteoma or osteoblastoma. Nidus size is the only reliable differentiator: under 2cm is osteoid osteoma, over 2cm is osteoblastoma. The distinction matters because osteoblastoma is more aggressive, less likely to resolve spontaneously, and requires more extensive surgical excision rather than minimally invasive RFA.

History. The classic complaint is night pain that wakes the patient from sleep and is relieved by aspirin or NSAIDs within 20-30 minutes. The pain is dull and aching, gradually increasing over months, and well localised: the patient can point to it with one finger. Ask specifically about the time of the pain, the NSAID response, the duration of symptoms (usually under 2 years) and any prior imaging.

Atypical presentations. The site of the lesion changes the story:

• Intra-articular - joint effusion and stiffness, mimicking synovitis
• Spinal - painful scoliosis in adolescents, the concavity towards the lesion
• Near a growth plate - growth disturbance is possible
• Hand and foot - swelling, with fusiform soft-tissue enlargement

Examination. Expect point tenderness over the lesion, possibly with soft-tissue swelling or warmth, and there may be muscle wasting from chronic pain. The range of motion is usually normal unless the lesion is intra-articular, and each site has its own signs.

Differential diagnosis. The lesions that share the history or the imaging, and what separates them:

Radiographs come first, then CT. MRI is supplementary, and a bone scan is kept for when the diagnosis is uncertain.

Radiographs. These may be normal in early cases or cancellous locations. The typical finding is cortical thickening with a central lucency, the nidus, and the amount of sclerosis varies with the location and duration of the lesion.

View larger

CT is the gold standard. Always request CT if osteoid osteoma is suspected. A thin-slice acquisition (1-2mm) through the affected area defines the nidus, its size, location and calcification, and CT is essential for treatment planning, including the RFA trajectory.

MRI can mislead. It shows extensive marrow and soft-tissue oedema, which may overestimate the extent of the lesion and appear aggressive enough to mimic infection or malignancy, while the nidus itself may be obscured by the reactive changes. It is still useful for intra-articular and spinal lesions.

View larger

View larger

The spine. Unilateral posterior-element pain can drive a painful scoliosis and demands targeted thin-slice CT. MRI emphasises the reactive marrow oedema; CT localises the sclerotic posterior-element lesion better, but a conspicuous lucent nidus may be absent.

View larger

Bone scan. A technetium bone scan is very sensitive, nearly 100%, and shows the double-density sign: focal uptake at the nidus within a larger area of reactive uptake. Use it when the diagnosis is uncertain, for instance when symptoms are classic but radiographs and initial CT are non-diagnostic, and to screen multiple sites or find an occult lesion. SPECT/CT localises the focus precisely.

View larger

Laboratory tests. These are typically normal: FBC, ESR, CRP and alkaline phosphatase are usually within normal limits. They mainly serve to exclude infection, with WCC, CRP and ESR raised in a Brodie abscess, rather than to diagnose osteoid osteoma.

The decision. Confirm the diagnosis from the clinical history (night pain, NSAID relief) and a CT showing a nidus under 2cm. Then assess the location: a lesion in a standard location proceeds to RFA, while the spine, an intra-articular site or the physis calls for the alternatives to be considered. Last come the patient's wishes: one who prefers non-surgical treatment can have a trial of NSAIDs, as the lesion may resolve in 2-5 years, and one who requires definitive treatment has RFA or surgical excision.

Algorithm

View larger

Non-operative management. It suits the patient who prefers conservative treatment, has a contraindication to anaesthesia, or has a lesion in a location that is difficult to access. The regimen is aspirin 650mg-1g twice daily or naproxen 500mg twice daily, continued until spontaneous resolution (average 3-4 years), with monitoring for GI side effects; its success is variable and symptoms continue until the lesion resolves.

Indications for intervention. Operative intervention is the standard approach for most patients seeking symptom relief. The absolute indications are a patient who desires definitive treatment, symptoms affecting quality of life, and a spinal lesion causing neurological symptoms. The relative indications are failed conservative management, NSAID intolerance or contraindication, and proximity to the growth plate requiring excision.

Radiofrequency ablation is the first-line treatment in most cases. It is a CT-guided percutaneous procedure with over 90% success and lower morbidity than open surgery.

Surgical excision, en bloc or by curettage, is indicated when RFA is contraindicated or has failed. Its morbidity is higher, but it is definitive.

Other ablation techniques. Besides RFA, the nidus can be ablated by:

• Cryoablation - an alternative near growth plates; it allows real-time monitoring of the treatment margin and may be useful near sensitive structures
• Laser ablation - similar to RFA
• MR-guided focused ultrasound - an emerging technique

View larger

Open excision. The complications of open excision and the factors that raise their risk are set out below.

Recurrence. Recurrence typically occurs within 2 years of treatment. Assessment looks for the return of the typical night pain pattern and repeats the CT to confirm a residual or recurrent nidus.

Treating it. Repeat RFA is successful in most cases, 85-90%, and is effective when a safe trajectory remains. Surgical excision follows if RFA fails twice, and en bloc excision offers a definitive cure.

View larger

After RFA. Rapid recovery is one of the major advantages of RFA: most patients return to normal activity within 1 week and are back to full activity within 1-2 weeks, compared to 6-12 weeks for surgical excision. They are discharged the same day or the next morning, bear weight as tolerated immediately, and take simple analgesia (paracetamol, NSAIDs) for 24-48 hours.

RFA follow-up. The wound is checked at 1 week, and there are no activity restrictions. Clinical follow-up is at 6 weeks, CT is repeated only if symptoms persist or recur, and the patient is discharged if asymptomatic at 6 months.

After surgical excision. Recovery takes 4-8 weeks, and the return to work and sport varies with the size of the excision (table below). Weight bearing depends on the extent of resection: as tolerated after a minor cortical window, protected for 4-6 weeks after a significant resection.

Excision rehabilitation. Activity is restricted for 4-6 weeks for bone healing, wound management is standard, and physiotherapy is added if needed.

Excision follow-up. Monitor for fracture if significant bone has been removed. Clinical review is at 6 weeks, 3 months and 6 months, with imaging only if symptoms recur and assessment of the bone-graft site if applicable.

Results of treatment. Both treatments achieve over 90% success. RFA has a primary success rate of 90-95%, and surgical excision succeeds in 90-95%, within a range of 88-100%. After successful treatment long-term cure is expected in over 95%, and the prognosis is excellent: osteoid osteoma is benign, with no risk of malignant transformation.

Prognostic factors. Outcomes are better with a cortical location (the best RFA access), complete ablation or excision of the nidus, and a small nidus under 1cm. A cancellous or intra-articular location, a large nidus approaching 2cm and a spinal location, with its technical challenges, are less favourable.

Function. After RFA patients make a full return to pre-morbid function, with no long-term restrictions and excellent satisfaction. After surgical excision recovery is generally full; a residual bone defect may remain on imaging, but it rarely causes functional limitation.

Global Epidemiology

Osteoid osteoma accounts for roughly 10-12% of benign bone tumours and an estimated 2-3% of all primary bone tumours, with a consistent young-male predominance (peak 10-25 years, M:F approximately 2:1) reported across European, North American, and Asian series. There are no significant ethnic differences in incidence. The lower limb (femur and tibia) dominates, with the spine involved in roughly 10-15% of cases. Large multicentre and meta-analytic cohorts confirm this distribution: the European multicentre spinal series of Beyer et al. (Neuroradiology 2019, DOI) and the 749-patient meta-analysis of Sangiorgio et al. (Eur Spine J 2023, DOI) both report spinal lesions concentrated in the lumbar and thoracic posterior elements of adolescents and young adults.

Guideline & Society Positions

There is no single dedicated international clinical practice guideline for osteoid osteoma; practice is shaped by interventional-radiology and orthopaedic-oncology society consensus. The table below synthesises the dominant positions.

Registry & Evidence Synthesis

Osteoid osteoma is benign and is not captured by arthroplasty joint registries; the closest equivalent to registry-level evidence is pooled multicentre data and meta-analysis. The strongest synthesis is Sangiorgio et al. (Eur Spine J 2023, DOI): across 31 studies and 749 spinal cases, RFA and surgery achieved similar success (88.6% vs 85.6%) and recurrence (6.7% vs 5.6%), with fewer complications after RFA (4.4% vs 7.8%). The original comparative landmark, Rosenthal et al. (J Bone Joint Surg Am 1998, DOI), reported equivalent recurrence (12% RFA vs 9% surgery) with dramatically shorter hospital stay (0.2 vs 4.7 days).

Practice Variation

Referral Pathway

Across high-income settings, CT-guided RFA is delivered through interventional radiology in metropolitan tertiary centres, with rural and remote patients commonly transferred for treatment. Suspected osteoid osteoma should be referred to an orthopaedic surgeon or musculoskeletal oncology unit, with interventional radiology involved for ablation and spinal-surgery or neurosurgery input for spinal lesions.